INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Superbugs and the Resistance Crisis

Harmanjot Kaur*, Amanpreet Kaur, Jyoti Sharma

PCTE Group of Institutes, Ludhiana.

ARTICLE INFO

Published: 21 Apr 2026
Keywords:
Superbugs, Resistance Crisis, antibiotic resistance, multidrug-resistant (MDR) microorganisms
DOI:
10.5281/zenodo.19677370

ABSTRACT

In the twenty-first century, antibiotic resistance has become one of the biggest risks to public health worldwide. In clinical, veterinary, and agricultural contexts, the uncontrolled and sometimes irrational use of antibiotics has sped up the evolution of multidrug-resistant (MDR) microorganisms, also known as "superbugs." These resistant strains impair the efficacy of conventional therapies, resulting in longer hospital stays, more medical expenses, and a higher death rate. This article offers a thorough summary of the processes by which bacteria become resistant, such as biofilm development, efflux pump activation, target change, and enzymatic destruction. Antibiotic misuse, inadequate infection control procedures, and a lack of innovative medication development are some of the major contributing variables that are also examined. The article also outlines new and existing approaches to address this developing epidemic, such as phage treatment, quick diagnostic tools, antimicrobial stewardship programs, the creation of novel antimicrobial drugs, and international policy initiatives. It takes coordinated efforts from the scientific, medical, and policy domains to address antibiotic resistance. By assessing recent developments and highlighting important gaps in our collective response to this epidemic, this study seeks to inform and encourage such actions

INTRODUCTION

Since their discovery in the early 1900s, antibiotics have been a vital component of contemporary medicine. An important turning point in the treatment of bacterial illnesses was reached in 1928 when Alexander Fleming discovered penicillin. Its widespread use during World War II ushered in the age of antibiotics and significantly decreased the number of fatalities from infected wounds (Davies & Davies, 2010). Once-fatal illnesses including pneumonia, syphilis, TB, and sepsis were curable with the advent of antibiotics in clinical practice, which resulted in sharp drops in mortality and improvements in quality of life. Complex surgical treatments, chemotherapy, and

***Corresponding Author:** Harmanjot Kaur
Address: *Assistant Professor, Faculty of Pharmaceutical Sciences, PCTE Group of Institutes, Ludhiana*
Email ✉: hansraharman3@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

critical care techniques that normally carried unacceptable infection risks were made possible by antibiotics (Ventola, 2015). However, the rise of microbes resistant to antibiotics is posing a growing danger to the efficacy of these life-saving medications. When bacteria develop defenses against the medications intended to eradicate them, antibiotic resistance results. Often referred to as "superbugs," these resistant organisms make conventional therapies ineffective, which results in more frequent infections, greater transmission, longer hospital stays, higher healthcare expenses, and higher death rates (Laxminarayan et al., 2013). One of the top ten worldwide public health risks that humanity is now experiencing is antimicrobial resistance (AMR), according to the World Health Organization (WHO, 2020).

Human activity has greatly increased antibiotic resistance, even though it is a normal evolutionary response. The overuse and irrational use of antibiotics in agriculture, veterinary medicine, and human medicine have produced powerful selection pressures that enable resistant strains to endure and spread. For instance, despite their inefficiency against viruses, antibiotics are frequently recommended improperly for viral diseases such as the common cold and influenza (Llor & Bjerrum, 2014). In addition, many patients stop taking antibiotics before the recommended course of therapy is finished, as soon as their symptoms subside. By exposing bacteria to sub-lethal levels, this behaviour encourages the survival and growth of partly resistant strains (Holmes et al., 2016).

In many parts of the world, especially in low- and middle-income countries (LMICs), antibiotics are readily available over the counter without a prescription. Unregulated access, combined with inadequate public awareness, results in widespread misuse (Morgan et al., 2011) In animal husbandry, antibiotics are also widely utilized as growth boosters and preventative measures in addition to treating illnesses. Animal products, environmental pollution, or direct contact can all spread the resistant germs that develop in cattle to people (Van Boeckel et al., 2015). Resistant microbes can also flourish in healthcare environments. Antibiotics are commonly used in hospitals, where patients are more susceptible, particularly in intensive care units. The transmission of multidrug-resistant organisms is facilitated by poor infection control measures, such as reusing equipment, not washing hands, and not maintaining proper sanitation. (Magill and others, 2014). Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii, and Klebsiella pneumoniae are a few of the most common hospital-acquired pathogens (CDC, 2019). One of the most significant is the shocking deceleration of antibiotic research. The identification of new antibiotics has decreased remarkably in the last several decades. Scientific hurdles, lengthy development periods, regulatory obstacles, and dismal economic prospects have discouraged numerous pharmaceutical firms to stop antibiotic research (Renwick et al., 2016). Bacteria, however, keep changing and adapting, often within a few months, rendering once-effective medications useless. The absence of new antibiotics in the pipeline has left clinicians with few alternatives for treating the infections caused by carbapenem-resistant Enterobacteriaceae (CRE) and other highly resistant Gram-negative bacteria (CDC, 2019).

This article aims to provide a comprehensive understanding of antibiotic resistance in the 21st century. It will explore the various mechanisms bacteria use to resist antibiotics, including biofilm formation, efflux pumps, target site modification, and enzymatic degradation. Additionally, it will examine the key contributors to the resistance crisis, such as misuse in healthcare and agriculture, lack of innovation, and weak policy enforcement.

Finally, it will evaluate current and emerging solutions—including phage therapy, rapid diagnostics, antimicrobial stewardship, and global surveillance—that can collectively contribute to managing this growing epidemic. A multidisciplinary, globally coordinated approach is essential to safeguarding the efficacy of antibiotics for future generations.

1. Mechanisms of Antibiotic Resistance

Bacteria have evolved varied and complex mechanisms to resist the activity of antibiotics. These mechanisms of resistance can be intrinsic (naturally occurring in certain species) or acquired (obtained by mutation or horizontal gene transfer). Knowledge of these mechanisms is important for the formulation of new antimicrobial measures and the maintenance of the effectiveness of current drugs (Davies & Davies, 2010).

The major mechanisms of antibiotic resistance include:

1.1 Enzymatic Inactivation of Antibiotics

One of the main resistance mechanisms is enzymatic modification or degradation of antibiotics, preventing them from reaching or binding to their sites of action. The most prevalent are β-lactamases, which cleave the β-lactam ring of penicillins, cephalosporins, carbapenems, and monobactams, rendering them inactive. Carbapenem-resistant bacteria produce enzymes like KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi metallo-β-lactamase), which disable even last-resort antibiotics (Bush & Bradford, 2016). Additional enzymes include chloramphenicol acetyltransferase, which deactivates chloramphenicol, and aminoglycoside-modifying enzymes, which change the structure of aminoglycosides like gentamicin (Davies & Davies, 2010).

1.2 Target Site Modification

Antibiotic binding sites may be modified by bacteria, making it more difficult for medications to bind and carry out their intended functions. For example, erythromycin and other macrolides cannot bind to ribosomal subunits when erm genes methylate 23S rRNA. Additionally, fluoroquinolone binding is decreased by mutations in DNA gyrase or topoisomerase IV, which results in resistance to medications like ciprofloxacin (Hooper & Jacoby, 2016). Moreover, the traditional mechanism of resistance in MRSA is the development of an alternative penicillin-binding protein (PBP2a) that has a poor affinity for β-lactams (Chambers & DeLeo, 2009).

1.3 Reduced Permeability

A major mechanism of antibiotic resistance is reduced permeability, especially in Gram-negative bacteria because of their distinct outer membrane, which prevents drugs from entering (Pagès et al., 2008). In contrast to Gram-positive bacteria, which have a single, thick layer of peptidoglycan, Gram-negative bacteria have an outer membrane made up of phospholipids, lipopolysaccharides (LPS), and porin channels that control the entrance of tiny molecules like antibiotics (Nikaido, 2003). Resistance to third-generation cephalosporins and carbapenems has been closely linked to the loss of OmpK35 and OmpK36 porins in Klebsiella pneumoniae (Doménech-Sánchez et al., 2003). A carbapenem antibiotic that particularly employs OprD to enter the bacterial cell, imipenem resistance in Pseudomonas aeruginosa is caused by mutations or deletions of OprD porin (Quale et al., 2006). E. Coli bacteria that express less OmpF are less susceptible to fluoroquinolones and β-lactam antibiotics (Delcour, 2009).

1.4 Active Efflux Pumps

Antibiotics are actively exported from bacterial cells by membrane proteins called efflux pumps, which lowers drug concentrations and promotes multidrug resistance (MDR). Both Gram-positive and Gram-negative bacteria have these systems, which have the ability to expel a wide variety of antimicrobials (Sharma et al., 2022).Tetracyclines, fluoroquinolones, and certain penicillins are among the several antibiotics that the AcrAB-TolC pump may eliminate from E. coli, a common gut bacterium. Because of this, illnesses brought on by drug-resistant E. coli are more difficult to cure (Wang et al., 2020). Strong antibiotics including carbapenems, fluoroquinolones, and chloramphenicol are eliminated by the MexAB-OprM pump in Pseudomonas aeruginosa, a bacterium that infects wounds and lungs. In hospitals, this pump aids in the survival of germs, particularly in critically ill patients (Morita et al., 2021). The NorA pump in Staphylococcus aureus eliminates medications such as fluoroquinolones. This pump makes certain drugs less effective against infections caused by S. aureus (Lee et al., 2022).

1.5 Horizontal Gene Transfer (HGT)

One of the main ways that bacteria can pick up antibiotic resistance genes from other bacteria, even from other species, is by horizontal gene transfer, or HGT. HGT allows bacteria to quickly acquire new properties by transferring genetic material through three main processes: conjugation, transformation, and transduction. This is in contrast to vertical gene transfer, which happens from parent to child. Through a pilus, conjugation involves the direct transfer of resistance genes from one bacterium to another, frequently via plasmids carrying numerous resistance genes. One well-known example is the NDM-1 gene, which confers carbapenem resistance and is often transferred between Klebsiella pneumoniae and E. coli by plasmid-mediated conjugation (Bush & Bradford, 2016). Free DNA fragments from the environment are taken up by bacteria during transformation and incorporated into their genome; for example, Streptococcus pneumoniae can acquire genes that make them resistant to penicillin.Bacteriophages, which are viruses that infect bacteria, can accidently transfer resistance genes from one bacterium to another through a process known as transduction. For instance, Staphylococcus aureus can acquire erythromycin resistance genes by phage-mediated transduction (Chambers & DeLeo, 2009).



Figure 1: Major Mechanisms of Antibiotic Resistance in Bacteria

Table 1: Common antibiotic-resistant pathogens

Pathogen	Resistance Characteristics	Common Infections	Treatment Challenges
MRSA	Resistant to methicillin	Skin, bloodstream	Limited effective antibiotics
VRE	Resistant to vancomycin	UTIs, bloodstream	Few therapeutic options
CRE	Carbapenem-resistant	UTIs, pneumonia	High mortality
ESBL *E. coli*	Produces extended-spectrum β-lactamases	UTIs, abdominal infections	Requires carbapenems
Pseudomonas aeruginosa	Multi-drug resistant (MDR)	Respiratory, wound	Efflux pumps, biofilm formation
Acinetobacter baumannii	Multi-drug resistant (MDR)	ICU infections	Limited options; often requires colistin

2. Causes and Contributing Factors of Antibiotic Resistance:

2.1 Antibiotic Overuse and Abuse in Human Medicine: One of the main causes of resistance is the inappropriate prescription and use of antibiotics. Since they have little therapeutic impact against viral illnesses like the common cold, influenza, or sore throat, antibiotics are frequently recommended improperly (Ventola, 2015). Additionally, patient noncompliance, such as discontinuing antibiotic treatment too soon, promotes the survival and growth of partly resistant bacterial populations. The issue is made worse by self-medication, especially in nations where antibiotics are sold over-the-counter (Morgan et al., 2011).

2.2 Inappropriate Use in Animal Husbandry and Agriculture: Antibiotic usage for illness prevention and growth promotion in aquaculture, poultry, and cattle greatly increases resistance. Humans may get resistant bacteria from animals by direct contact, ingestion of animal products, or environmental contamination (Landers et al., 2012). For example, agricultural antibiotic practices have been connected to resistant strains of Salmonella and Escherichia coli, posing a risk to public health (Marshall & Levy, 2011).

2.3 Antibiotic Residue Contamination in the Environment: Significant antibiotic residues are frequently found in hospital effluents, agricultural runoff, and waste from pharmaceutical manufacture. When these leftovers get into soil and water environments, they exert a selection pressure on environmental microorganisms, encouraging the development of resistance (Larsson, 2014). Research conducted in China and India has revealed that rivers close to manufacturing facilities contain significant concentrations of antibiotics, which is enough to promote the development of resistance (Kristiansson et al., 2011).

2.4 Poor Infection Prevention and Control in Healthcare Settings: Weak infection control practices in hospitals and clinics significantly contribute to the spread of antibiotic-resistant organisms. Overcrowded wards, inadequate sterilization of medical equipment, poor hand hygiene, and improper isolation of infected patients facilitate rapid transmission of resistant strains such as MRSA, CRE, and VRE (Allegranzi & Pittet, 2009). Healthcare workers may unintentionally transfer resistant bacteria between patients when infection-control protocols are not strictly followed. ICU settings, where invasive procedures are common, are especially vulnerable to outbreaks of multidrug-resistant organisms

(Magill et al., 2014). These lapses not only increase incidence but also promote selective pressure by necessitating broader-spectrum antibiotic use.

2.5 Lack of Rapid and Accurate Diagnostic Tools: In many regions, limited access to reliable diagnostic tests leads clinicians to prescribe antibiotics empirically, even when bacterial infection is uncertain. This overuse of broad-spectrum agents adds significant selective pressure, accelerating the development of resistance (O'Neill, 2016). Without precise diagnostics, viral infections such as dengue, influenza, or COVID-19 are often mistakenly treated with antibiotics. Point-of-care tests and culture facilities are inadequate or unavailable in rural and low-income healthcare settings, resulting in unnecessary antibiotic prescriptions (Okeke et al., 2005). Thus, diagnostic gaps contribute directly to inappropriate antibiotic exposure.

2.6 Limited Development of New Antibiotics: Pharmaceutical companies have reduced investment in antibiotic research due to low profitability, high development costs, and strict regulatory barriers (Spellberg et al., 2013; Ventola, 2015). Consequently, few novel antibiotics have been developed in recent decades, while bacteria continue to evolve resistance faster than new drugs become available (Renwick et al., 2016; Laxminarayan et al., 2013). Because of limited alternatives, clinicians often rely on last-line agents such as colistin, but this has resulted in the emergence of colistin-resistant strains, further worsening the global resistance crisis (Li et al., 2006; Liu et al., 2016).

2.7 Public Misconceptions and Lack of Awareness: Public misconceptions and low health awareness significantly contribute to irrational health behaviours. Many people still believe antibiotics work for viral infections or stop treatment early, leading to improper self-medication and delayed care (Nutbeam, 2000; WHO, 2013). Misinformation from social networks and cultural beliefs further promotes unsafe practices and increases stigma toward illnesses such as TB or HIV, reducing treatment seeking and worsening disease spread (Banerjee & Rai, 2020). Improving health literacy through targeted education and pharmacist-led counselling is therefore essential.

2.8 Substandard, Counterfeit, and Low-Quality Antibiotics: Poor-quality antibiotics—containing insufficient active ingredients or degraded formulations—are a hidden but critical factor in resistance development. These sub-therapeutic concentrations fail to eliminate pathogenic bacteria completely, enabling the survival of partially resistant strains (Kelesidis & Falagas, 2015). Counterfeit antibiotics are particularly common in low- and middle-income countries, where supply chains are poorly regulated. The World Health Organization reports that up to 10% of medical products in developing nations are substandard or falsified, contributing to treatment failure and rising resistance rates (WHO, 2017).

Table 2: Key Causes of Antibiotic Resistance

Cause	How It Leads to Resistance	Examples
Misuse in humans	Wrong or incomplete use helps bacteria survive	Taking antibiotics for cold/flu, incomplete course.
Use in animals & farming	Low-dose use creates resistant bacteria.	Growth promoters in poultry, aquaculture.

Poor hospital hygiene	Easy spread of resistant microbes in unclean settings.	MRSA outbreaks.
Lack of proper diagnostics	Broad-spectrum antibiotics used unnecessarily.	Treating fever without tests.
Substandard or fake antibiotics	Low drug levels promote partial survival.	Poor-quality amoxicillin, ciprofloxacin.
Environmental contamination	Antibiotic waste selects resistant organisms.	Pharma waste, sewage discharge.
Limited new antibiotics	Old drugs become ineffective with no replacements.	Rising carbapenem resistance.
Global travel	Resistant strains spread across countries.	International spread of NDM-1.
Low public awareness	Misbeliefs lead to wrong antibiotic use.	Stopping medicine once feeling better.

4. Impact on Public Health:

Antibiotic resistance has far-reaching consequences for global health, healthcare systems, and society. Its impact can be categorized into four key areas:

4.1 Increased Morbidity and Mortality:

Antibiotic resistance significantly increases the severity and duration of infections, leading to higher morbidity and mortality. Infections caused by multidrug-resistant organisms, such as carbapenem-resistant Enterobacteriaceae (CRE), are associated with mortality rates as high as 50% in hospitalized patients (Centers for Disease Control and Prevention [CDC], 2019). Methicillin-resistant Staphylococcus aureus (MRSA) infections can lead to serious complications, including sepsis, pneumonia, and endocarditis, especially in immunocompromised individuals or the elderly (Chambers & DeLeo, 2009). Resistant bacteria often survive standard antibiotic therapy, leading to chronic or recurrent infections. For example, urinary tract infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli frequently fail first-line therapy, increasing the risk of pyelonephritis and kidney damage (Laxminarayan et al., 2013). Such treatment failures prolong illness and increase the likelihood of severe outcomes.

4.2 Longer Hospital Stays and Increased Healthcare Burden:

Patients infected with resistant pathogens generally require extended hospitalizations due to complex treatment regimens and the need for advanced care, including intravenous antibiotics and frequent monitoring. European studies estimate that multidrug-resistant infections prolong hospital stays by 8–12 days per patient on average (Organisation for Economic Co-operation and Development [OECD], 2018). Extended hospitalization increases the risk of additional infections and consumes considerable healthcare resources. Intensive care units (ICUs), where patients are critically ill, are particularly vulnerable to outbreaks of multidrug-resistant organisms. Infections such as ventilator-associated pneumonia and bloodstream infections require prolonged ICU care, specialized isolation protocols, and increased staffing, all of which escalate the healthcare burden (Magill et al., 2014).

4.3 Threats to Modern Medical Procedures and Global Health Security:

The rise of resistant bacteria threatens the safety of routine medical interventions. Surgeries, chemotherapy, organ transplants, and neonatal care all rely on effective antibiotics to prevent and treat infections. Without reliable therapies, even minor surgical procedures can become high-risk, and the success of critical medical interventions may be compromised (Ventola, 2015). Moreover, antibiotic-resistant pathogens represent a global health security concern. Resistant bacteria can spread rapidly across countries through travel, trade, and migration. For instance, NDM-1-producing bacteria, initially identified in India, have been reported worldwide, demonstrating the potential for international dissemination (Bush & Bradford, 2016).

5. Strategies to Combat Antibiotic Resistance:

Addressing antibiotic resistance requires a multifaceted approach, integrating interventions at clinical, community, agricultural, and policy levels. Effective strategies aim to preserve the effectiveness of existing antibiotics, reduce the emergence of resistant strains, and promote the development of novel therapies.

5.1 Antimicrobial Stewardship Programs (ASPs): Antimicrobial stewardship programs are coordinated interventions designed to improve and measure the appropriate use of antibiotics. These programs focus on selecting the right antibiotic, at the correct dose and duration, to maximize therapeutic outcomes while minimizing resistance development (Dyar et al., 2017). Hospitals implementing ASPs have demonstrated reductions in antibiotic consumption, lower rates of multidrug-resistant infections, and decreased healthcare costs. For example, a meta-analysis revealed that ASP implementation in hospitals led to a 19% reduction in overall antibiotic use and a 37% decrease in Clostridioides difficile infections (Baur et al., 2017).

5.2 Development of Novel Antimicrobial Agents:

The rise of multidrug-resistant bacteria has created an urgent need for novel antimicrobial agents. Innovative strategies include β-lactamase inhibitors, which restore the effectiveness of β-lactam antibiotics against resistant bacteria (Bush & Bradford, 2016); antimicrobial peptides, which disrupt bacterial membranes and are less prone to resistance (Mahlapuu et al., 2016); and phage therapy, which uses bacteriophages to specifically target pathogenic bacteria (Abedon et al., 2017). Researchers are also developing synthetic compounds that inhibit bacterial quorum sensing, cell wall synthesis, or essential metabolic pathways (Laxminarayan et al., 2013). Despite challenges such as high costs and regulatory hurdles, continued investment in these approaches is essential to combat antibiotic resistance and ensure effective treatments in the future (Renwick et al., 2016).

5.3 Public Education and Awareness Campaigns:

These initiatives aim to inform communities about the proper use of antibiotics, emphasizing that antibiotics are ineffective against viral infections such as influenza, the common cold, or COVID-19 (WHO, 2015). Education also stresses the importance of completing prescribed courses to prevent survival of partially resistant bacteria (Nutbeam, 2000). Targeted campaigns, including mass media messages, community workshops, and pharmacist-led counseling, have been shown to improve patient behavior and adherence to treatment guidelines (Morgan et al., 2011). Additionally, raising awareness about vaccination as a preventive measure reduces the incidence of bacterial infections, indirectly lowering the demand for antibiotics. In countries where antibiotics are available over-the-counter, public campaigns can discourage self-medication,

ensuring that antibiotics are used only when prescribed by healthcare professionals (Ventola, 2015).

5.4 Infection Prevention and Control (IPC) Measures:

Infection Prevention and Control (IPC) measures are essential to limit the spread of antibiotic-resistant bacteria in healthcare and community settings. Effective IPC strategies include proper hand hygiene, use of personal protective equipment (PPE), sterilization of medical equipment, and isolation of patients infected with multidrug-resistant organisms. Environmental sanitation, including regular cleaning of hospital surfaces and monitoring of high-risk areas, further reduces the risk of transmission. In intensive care units (ICUs), where invasive procedures are common, strict adherence to IPC protocols is critical to prevent outbreaks (Allegranzi & Pittet, 2009).

REFERENCES

1. Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. *Microbiology and Molecular Biology Reviews*, 74(3), 417–433.
2. Ventola, C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. *Pharmacy and Therapeutics*, 40(4), 277–283.
3. Laxminarayan, R., Duse, A., Wattal, C., et al. (2013). Antibiotic resistance—the need for global solutions. *The Lancet Infectious Diseases*, 13(12), 1057–1098.
4. World Health Organization (WHO). (2020). *Antimicrobial resistance*.
5. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014 Dec;5(6):229-41. doi: 10.1177/2042098614554919.
6. Holmes, A. H., Moore, L. S. P., Sundsfjord, A., et al. (2016). Understanding the mechanisms and drivers of antimicrobial resistance. *The Lancet*, 387(10014), 176–187.
7. Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, Teillant A, Laxminarayan R. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A. 2015 May 5;112(18):5649-54. doi: 10.1073/pnas.1503141112.
8. Magill, S. S., Edwards, J. R., Bamberg, W., et al. (2014). Multistate point-prevalence survey of health care–associated infections. *New England Journal of Medicine*, 370(13), 1198–1208.
9. Centers for Disease Control and Prevention (CDC). (2019). *Antibiotic Resistance Threats in the United States, 2019*. U.S. Department of Health and Human Services.
10. Renwick, M. J., Brogan, D. M., & Mossialos, E. (2016). A critical assessment of incentive strategies for novel antibiotics. *Journal of Antibiotics*, 69(2), 73–88.
11. Bush, K., & Bradford, P. A. (2016). β-Lactams and β-lactamase inhibitors: An overview. *Cold Spring Harbor Perspectives in Medicine*, *6*(8), a025247.
12. Hooper, D. C., & Jacoby, G. A. (2016). Topoisomerase inhibitors: Fluoroquinolone mechanisms of action and resistance. *Cold Spring Harbor Perspectives in Medicine*, *6*(9), a025320.
13. Chambers, H. F., & DeLeo, F. R. (2009). Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology, 7(9), 629–641.
14. Pagès, J. M., James, C. E., & Winterhalter, M. (2008). The porin and the permeating antibiotic: A selective diffusion barrier in Gram-negative bacteria. *Nature Reviews Microbiology*, *6*(12), 893–903.

15. Nikaido, H. (2003). Molecular basis of bacterial outer membrane permeability revisited. *Microbiology and Molecular Biology Reviews*, *67*(4), 593–656.
16. Delcour, A. H. (2009). Outer membrane permeability and antibiotic resistance. *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics*, *1794*(5), 808–816.
17. Doménech-Sánchez, A., Hernández-Allés, S., Martínez-Martínez, L., Benedí, V. J., & Albertí, S. (2003). Identification and characterization of a new porin gene of *Klebsiella pneumoniae*: its role in β-lactam antibiotic resistance. *Journal of Bacteriology*, *185*(13), 4113–4119.
18. Quale, J., Bratu, S., Landman, D., & Heddurshetti, R. (2006). Molecular epidemiology and mechanisms of carbapenem resistance in *Pseudomonas aeruginosa* endemic to Brooklyn, New York. *Clinical Infectious Diseases*, *42*(5), 738–744.
19. Sharma, A., Bansal, S., & Singh, R. (2022). Mechanisms and clinical significance of efflux-mediated antibiotic resistance. *Journal of Infection and Public Health*, 15(2), 200–208.
20. Wang, X., Li, Z., Zeng, J., et al. (2020). Characterization of the AcrAB-TolC efflux system in multidrug-resistant *Escherichia coli*. *Frontiers in Cellular and Infection Microbiology*, 10, 331.
21. Morita, Y., Tomida, J., & Kawamura, Y. (2021). MexXY multidrug efflux system of *Pseudomonas aeruginosa*. *Frontiers in Microbiology*, 12, 703800.
22. Lee, Y., Kim, H. K., & Cho, S. H. (2022). Efflux-mediated fluoroquinolone resistance in clinical *Staphylococcus aureus* isolates. *Journal of Global Antimicrobial Resistance*, 28, 76–83.
23. Morgan, D. J., Okeke, I. N., Laxminarayan, R., Perencevich, E. N., & Weisenberg, S. (2011). Non-prescription antimicrobial use worldwide: a systematic review. *The Lancet Infectious Diseases*, 11(9), 692–701.
24. Landers, T. F., Cohen, B., Wittum, T. E., & Larson, E. L. (2012). A review of antibiotic use in food animals: perspective, policy, and potential. *Public Health Reports*, 127(1), 4–22.
25. Marshall, B. M., & Levy, S. B. (2011). Food animals and antimicrobials: impacts on human health. *Clinical Microbiology Reviews*, 24(4), 718–733.
26. Larsson, D. G. J. (2014). Pollution from drug manufacturing: review and perspectives. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 369(1656), 20130571.
27. Kristiansson, E., et al. (2011). Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and novel resistance genes. *PLoS ONE*, 6(2), e17038.
28. Allegranzi, B., & Pittet, D. (2009). Role of hand hygiene in healthcare-associated infection prevention.
29. Magill, S. S. et al. (2014). Multistate point-prevalence survey of healthcare-associated infections.
30. O'Neill, J. (2016). Tackling Drug-Resistant Infections Globally.
31. Okeke, I. N. et al. (2005). Diagnostics as essential tools for containing antibacterial resistance.
32. Spellberg, B., Bartlett, J., & Gilbert, D. N. (2013). The future of antibiotics and resistance.
33. Banerjee, D., & Rai, M. (2020). Social stigma during public health emergencies.
34. Nutbeam, D. (2000). Health literacy as a public health goal. *Health Promotion International*.

35. World Health Organization (WHO). (2013). *Antimicrobial resistance: global report on surveillance*.
36. Kelesidis, T., & Falagas, M. E. (2015). Substandard/counterfeit antimicrobial drugs.
37. World Health Organization (2017). Global Surveillance and Monitoring System for Substandard and Falsified Medical Products.

HOW TO CITE: Harmanjot Kaur, Amanpreet Kaur, Jyoti Sharma, Superbugs and the Resistance Crisis, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 3438-3448, https://doi.org/10.5281/zenodo.19677370